Vilhelm Bohr is an Affiliate Professor at the Department of Cellular and Molecular Medicine , University of Copenhagen, affiliated with the Molecular Aging Program and Center for Healthy Aging . His research explores the interplay between DNA maintenance , mitochondrial biology , and aging , particularly in age-associated neurodegeneration and Alzheimer’s disease. Research Interests include: Molecular mechanisms linking NAD + metabolism to mitochondrial dysfunction and neurodegeneration Role of tau pathology in DNA damage and mitochondrial stress Impact of Aprataxin (APTX) and RECQL4 helicase defects on mitochondrial DNA integrity Pharmacological strategies to improve mitochondrial health via autophagy modulation Publications (2025-2024) span topics like NAD + biosynthesis, Werner/Rothmund-Thomson syndromes, tau nuclear functions, and mitochondrial turnover, with high citations and media attention. Collaborations extend to clinical tumor samples and CRISPR-based disease models.
Lisandra Stein Bernardes Ciampi Andrade is an Associate Professor in the Department of Clinical Medicine at Aalborg University's Faculty of Medicine, affiliated with the Center for Clinical Research. She holds an ORCID identifier (0000-0003-2367-2849) and an email lsbca@dcm.aau.dk. Her research focuses on fetal medicine, particularly pain assessment in fetuses, preterm birth prevention, and clinical applications of ultrasound in obstetrics. She was honored as 'Årets Underviser' (Teacher of the Year) by her peers in 2024, recognizing her high-level teaching. Collaborators include Louise Thomsen Schmidt Arenholt, Peter Derek Christian Leutscher, and Anya Sook Goldmann Eidhammer. Her work addresses fetal vascularity, gestational age assessment, and retrospective cohort studies in maternal-fetal medicine. Recent publications span topics like fetal cardiac interventions, chronic pain mechanisms in pregnancy, and international consensus guidelines for twin pregnancy management. She actively contributes to peer-reviewed journals such as Ultrasound in Obstetrics & Gynecology and Fetal Diagnosis and Therapy .
Anton Pottegård is a Professor at the University of Southern Denmark and Head of Research at Hospital Pharmacy Funen (Odense University Hospital). His work combines registry-based pharmacoepidemiological research with clinical investigations into deprescribing practices. Affiliation: University of Southern Denmark Secondary Role: Head of Research, Odense University Hospital Research interests focus on pharmacoepidemiology and clinical pharmacy , particularly real-world drug safety and deprescribing in geriatric care. His methodology emphasizes Danish healthcare registries for longitudinal analyses of medication patterns and adverse outcomes. Notable contributions include epidemiological analyses of opioid utilization , migraine treatments , and GLP-1 receptor agonists . He has developed frameworks for pharmacoepidemiological methodology and drug safety surveillance , co-authored over 300 publications, and led the REDO project on reducing opioid use in osteoarthritis. Additional activities include media commentary on TBE vaccination and tick-borne diseases , with 613 press/media appearances reflecting public health engagement. Supervised work includes 7 doctoral candidates and cross-national collaborations.
Anne Zebitz Eriksen is an Assistant Professor at the Department of Health Technology, Technical University of Denmark (DTU), specializing in Cell and Drug Technologies within Tailored Materials and Tissues. Her research integrates pharmaceutical science, biomedical engineering, and ophthalmology to develop advanced drug delivery systems and nanocarriers. University: Technical University of Denmark Department: Health Technology Academic Rank: Assistant Professor Research Interests: Her work focuses on liposome engineering, membrane translocation mechanisms, ocular drug delivery, and 3D stem cell-derived organoids. She actively contributes to addressing challenges in diabetic retinopathy, viral infections (e.g., SARS-CoV-2), and intestinal bioavailability. Article Trends: Recent publications highlight her expertise in lipid-based nanocarriers, ocular pharmacokinetics, and organoid models. Key themes include peptide transport optimization, antiviral protocols, and bioprinting perfusable vasculatures for tissue engineering. Supervision & Collaboration: She supervises PhD projects on microsystems for tissue actuation and bioprinted vasculatures, collaborating with institutions like DTU Health Tech. Her research aligns with UN SDGs for health and well-being, emphasizing innovative drug delivery solutions.
Jesper Østergaard serves as Professor of Pharmaceutical Physical Chemistry within the Department of Pharmacy at the Faculty of Health and Medical Sciences, University of Copenhagen. With over 20 years of continuous service at the institution, he progressed through the academic ranks from Assistant Professor (2003-2006) to Associate Professor (2006-2018) before attaining full Professorship in 2019. His academic journey began with a PhD in pharmaceutical sciences from the University of Copenhagen in 2003. Professor Østergaard's research focuses on advancing fundamental understanding of drug development processes, particularly transport, dissolution, release phenomena, and chemical stability/kinetics. His work emphasizes the interplay between physical chemical properties of drug substances and excipients with transport processes and kinetics related to drug delivery. He has developed novel analytical approaches for physical chemical characterization, including techniques for measuring diffusivity, molecular interactions, and partitioning. His research has significant implications for subcutaneous and intramuscular injectable formulations, with a key focus on developing biopredictive in vitro release testing platforms that emulate in vivo conditions. Current research directions include physicochemical profiling using Taylor dispersion analysis and affinity capillary electrophoresis, design and characterization of injectable depot formulations, development of in vitro release testing methods for long-acting injectables, and application of UV-Vis imaging for drug dissolution and release testing. His publication record demonstrates consistent output across these areas, with recent work emphasizing dissolution dynamics, biorelevant testing methods, and advanced analytical techniques. As an educator, Professor Østergaard is course responsible for the compulsory bachelor courses Pharmaceutical Physical Chemistry I and II, teaching approximately 200 pharmacy students annually. He also supervises master's students in pharmaceutical physical and analytical chemistry, continuing his commitment to training the next generation of pharmaceutical scientists.
Steen Larsen is an Associate Professor in the Department of Biomedical Sciences at the University of Copenhagen's Faculty of Health and Medical Sciences. He also holds a Visiting Professor position at the Medical University of Bialystok in Poland since 2018. Dr. Larsen leads the Exercise and Muscle Center for Healthy Aging and has established a laboratory specializing in mitochondrial analysis across various tissues since becoming an Assistant Professor in 2015. His educational background includes a Doctor of Medical Sciences (2014), M.Sc. in Human Physiology (2008), and B.Sc. in Chemistry (2007), all from the University of Copenhagen. Dr. Larsen's primary research focuses on understanding how lifestyle interventions (exercise, diet, drugs) affect whole-body metabolism and mitochondrial function, with particular attention to skeletal muscle and adipose tissue. His laboratory primarily studies human subjects but occasionally employs animal models. Dr. Larsen's recent publications (2024-2025) demonstrate a strong emphasis on mitochondrial physiology across various conditions including diabetes, obesity, statin treatments, and aging. His work spans from basic molecular mechanisms to clinical applications, with publications appearing in high-impact journals such as Cell Metabolism, Diabetologia, and Nature Communications. His research consistently connects mitochondrial function with metabolic health outcomes across different populations. As an educator, Dr. Larsen teaches medical students during their 4th and 5th semesters and supervises numerous bachelor's, master's, and currently four PhD students. He is frequently invited to present at major conferences including the European College of Sport Science and the American College of Sports Medicine.
Carmen Milian Guimera is a Postdoc researcher at the DTU Health Technology department of the Technical University of Denmark , specializing in Drug Delivery and Sensing . Her work focuses on developing advanced drug delivery systems targeting mucus penetration and pH-responsive release mechanisms. UN Sustainable Development Goals contributions: Healthcare innovation and drug delivery optimization Key Collaborators : Anders Boisen, Marjan Enbo Ghavami, Lise Hald Thamdrup Her research explores: Biomaterials for gastrointestinal applications Self-unfolding drug delivery foils Microneedle and micromotor technologies Polymeric device fabrication and testing Oral bioavailability enhancement In vitro/in vivo evaluation methodologies Recent publications demonstrate expertise in: Mucus-penetrating drug delivery systems Multi-compartment microcontainer platforms pH-targeted release mechanisms Biodegradable medical device design She has presented at major conferences on: Oral drug delivery innovations Microneedle applications Sequential release technologies
Per Damkier is a Clinical Professor at the University of Southern Denmark, affiliated with the Research Unit for Clinical Pharmacology in Odense. His career spans since 1996, focusing on drug-related education and research at SDU. Research interests: Pharmacogenomics (e.g., genetic variants in tamoxifen metabolism) Medicines during pregnancy and breastfeeding (e.g., acetaminophen's neurodevelopmental effects) Drug interactions (e.g., tamoxifen's pharmacokinetics) Education & Teaching : Formal pedagogical training (2006, 2010) Coordinated drug-related education in the Master of Medicine program Teaching methods: Lecture, case-based, research-based, eLearn platforms Exam formats: Essay, MCQ, OSCE, oral exams Supervision & Examination : Supervised 14 Master's students (1 active) and 4 undergraduate research year students (1 active) Co-supervised 9 PhD students (3 active) and served on 5 PhD assessment committees Member of Pharmacology Censor Corps; setter of national pharmacology exams Research Impact : Active in pregnancy pharmacology and drug safety , with over 300 publications Recent work focuses on acetaminophen's fetal effects, tamoxifen interactions, and paternal drug exposure risks Contributor to Danish national guidelines and digital educational resources
Tore B. Stage is a Professor and Research Leader at the Institute for Health Services Research (Clinical Pharmacology, Pharmacy and Environmental Medicine) at the University of Southern Denmark. His research focuses on individual variability in drug response, particularly drug interactions and pharmacogenetics, utilizing both in vitro models and clinical trials. Primary research areas: Pharmacogenetics Chemotherapy-Induced Peripheral Neuropathy Pharmacokinetic Modeling Drug Transport Mechanisms Key publications include mechanistic studies of neurotoxicity in cancer patients and translational models bridging in vitro and clinical findings. His work spans immunosuppressants, anticoagulants, and chemotherapeutic agents. Major scientific awards: Lundbeckfondens Talentpris (2017) DFF-Research Talent (2015) ISSX Poster Award (2017) Presidential Trainee Award (2016) Jason Morrow Trainee Award (2016) He supervises PhD students, including Mortensen, C. (2020-2022), on projects exploring chemotherapy-induced neuropathy mechanisms.
Katrine Lindholm Bøgh is a Professor and Head of the Research Group for Food Allergy at the National Food Institute, Technical University of Denmark (DTU). Her work focuses on developing diagnostic, preventive, and therapeutic strategies for food allergies, with a specific emphasis on understanding how physicochemical properties of food proteins influence allergy development versus tolerance. She leads interdisciplinary research at the intersection of immunology, food science, and sustainable nutrition. Current affiliations: DTU National Food Institute, Research Group for Food Allergy Academic rank: Professor Her research integrates Food Allergy , Molecular Allergology , and Allergenicity Assessment to investigate immune mechanisms triggered by protein modifications (e.g., hydrolysis, heat treatment) and exposure routes. She has pioneered studies on Alternative Protein Sources like insect, rapeseed, and microalgae to evaluate allergenic risks in sustainable foods. Recent publications highlight trends in European Union novel food approvals (2025) and mechanistic insights into cow’s milk allergy models (2024). Key themes include Sublingual Immunotherapy , Brown Norway Rat Models , and Protein Processing Effects on allergenicity. She supervises PhD students Yue S.R. and Shafie B., and leads major projects like: ALLEVIATE2: Novel food allergy immunotherapy strategies ALLPreT: Allergenicity Prediction Toolbox for novel foods SAFEPRO: Sustainable protein sources for future diets Her work aligns with UN Sustainable Development Goals (SDG 2, SDG 3), and she actively participates in international conferences and media outreach about food allergy risks in innovative protein sources.
Ann-Cathrine Dalgård Dunvald is a PhD and Guest Researcher at the Institute for Health Services Research , focusing on Clinical Pharmacology, Pharmacy, and Environmental Medicine . Her research centers on drug metabolism, pharmacokinetics, and interactions, particularly involving CYP3A4 , P-glycoprotein , and anticoagulant therapies . Key Research Areas: Drug Metabolism, Inflammation, Warfarin Efficacy, Dicloxacillin/Flucloxacillin Effects, Clinical Pharmacokinetics, Multimorbidity Management. Her recent work includes systematic reviews on collaborative care for multimorbidity and studies on antibiotic-anticoagulant interactions . Publications highlight translational approaches linking in vitro and clinical data , with a focus on type 2 diabetes and rheumatoid arthritis . She contributes to methodological frameworks in pharmacokinetic analysis and drug interaction studies.
Umberto Maria Battisti serves as Associate Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen, specializing in Medicinal Chemistry. His research focuses on developing novel radiopharmaceuticals for targeted cancer therapy and molecular imaging through advanced pretargeting strategies. Dr. Battisti's work centers on radiopharmaceutical chemistry with emphasis on tetrazine-based bioorthogonal systems . His group pioneers techniques for labeling isotopes like Astatine-211 (α-emitter for therapy), Fluorine-18, and Gallium-68 (for PET imaging), addressing critical challenges in in vivo stability and tissue penetration . Key innovations include BBB-penetrating agents for neurological applications and polar modifications to optimize pharmacokinetics. Analysis of his 2024-2025 publications reveals dominant trends in pretargeted theranostics , particularly comparative studies of tetrazine reactivity ( e.g. , polar vs. non-polar variants) and isotope-specific optimizations. Research spans oncology (FAPi inhibitors, tumor uptake enhancement) and neuroscience (brain imaging agents), with strong translational focus toward clinical applications of α-therapy and PET imaging. Dr. Battisti maintains an extensive collaborative network within Copenhagen's Department of Drug Design and Pharmacology, working closely with nuclear medicine specialists on radiochemistry, preclinical validation, and therapeutic applications. His team's interdisciplinary approach integrates synthetic chemistry, in vivo modeling, and imaging technology development.
Caroline Pehrson serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. Her institutional email address (acp@regionsjaelland.dk) indicates a clinical affiliation with the Danish regional health authority Regionsjaelland, suggesting her work bridges academic research and clinical practice. Dr. Pehrson's research focuses extensively on placental malaria and its impact on pregnancy outcomes. Her work spans multiple dimensions of malaria research including vaccine development, parasite sequestration mechanisms, and fetal development complications. She has made significant contributions to understanding how Plasmodium falciparum interacts with placental tissue through chondroitin sulfate A binding. Analysis of her publication record reveals a strong emphasis on translational research, with studies ranging from basic molecular mechanisms to clinical applications. Her work on the pre-clinical and clinical development of placental malaria vaccines represents an important contribution to this specialized field. The high citation counts on several of her papers (particularly the PLOS Pathogens article with 82 citations) indicate substantial impact in the malaria research community. Dr. Pehrson maintains extensive collaborations with leading researchers in the field, particularly with Theander, Salanti, and Nielsen, suggesting she is an integral part of a well-established research network focused on infectious diseases and pregnancy.
Lone Bak Posada is a Clinical Assistant Professor at the Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark. She is actively involved in clinical research with a focus on pharmacology and drug interactions in vulnerable patient populations. Research Interests: Her work primarily centers on clinical pharmacology, especially pharmacokinetics and drug interactions in critically ill pediatric patients. She investigates the therapeutic challenges of managing antiepileptic drugs such as sodium valproate, lamotrigine (Lamictal), phenobarbital, and topiramate in complex clinical settings involving polypharmacy. Recent Research Trends: Her 2025 case report highlights a real-world example of persistent low antiepileptic drug concentrations due to multiple potential drug interactions, particularly in the context of co-administration with meropenem in a critically ill child. This underscores the importance of therapeutic drug monitoring and pharmacokinetic considerations in pediatric intensive care. Scientific Contributions: Active contributor to clinical case literature in pharmacology. Focus on improving medication safety in pediatric critical care. Advising and Grants: No information available regarding student supervision or grant funding. Further details may be available through institutional sources. Labs and Research Teams: Affiliated with clinical research activities at Aalborg University’s Department of Clinical Medicine, likely collaborating within pharmacology and critical care networks. Specific lab or team names are not mentioned in the provided text.
Lisa Greve Routhe is an Associate Professor in the Department of Clinical Medicine at the Faculty of Medicine, Aalborg University, Denmark. Her research spans neuroscience and clinical pharmacology, with a focus on the blood-brain barrier, neurodegeneration, and medication use in healthcare systems. Research Interests: Her work investigates the role of iron metabolism (particularly ferroportin and hepcidin) in the neurovascular unit, glial-endothelial interactions, and neuroinflammatory mechanisms contributing to neurodegenerative diseases. She also explores practical aspects of pharmacotherapy, including medication waste in outpatient settings and renal risk drug management. Publication Trends: Her recent publications (2024–2025) reflect a dual trajectory: (1) experimental neuroscience studies on brain angioarchitecture remodeling and neuroinflammation, and (2) applied health services research on medication efficiency and safety. This indicates a strong interdisciplinary profile combining basic science with clinical and public health applications. Scientific Engagement: Her research has received media attention, notably a 2020 press piece titled Forskere mistænker jern for skurkerolle ifm neurodegenerative sygdomme , highlighting public outreach. She has contributed to the development of clinical guidelines for renal risk medications in Denmark. Collaborations and Projects: She was a Co-Investigator in the 2017–2019 project Epigenetic regulation of ferroportin in the neurovascular unit , funded by Scleroseforeningen. She collaborates with prominent researchers such as Torben Moos, Martin S. Thomsen, and Sigrun Helgudóttir. She has co-authored numerous peer-reviewed journal articles, reviews, and a PhD thesis, indicating active research leadership. Laboratory/Team Affiliation: While no specific lab name is mentioned, her work appears to be conducted within a neuroscience and blood-brain barrier research group at Aalborg University, likely integrated with clinical pharmacy and hospital collaboration networks in the North Denmark Region.
